Aripiprazole is used alone or together with other variables to treat mental conditions such as atypical I disorder manic-depressive illness, major depressive episode, and schizophrenia. It is also ...

Aripiprazole (Abilify, Otsuka Pharmaceuticals Europe) is an antipsychotic with partial dopamine D2 and D3 agonistic properties. It has a UK marketing authorisation 'for the treatment up to 12 weeks of ...

This trial was sponsored by Otsuka Pharmaceutical Co. Initially approved in November, over ABILIFY Tablets should be taken once daily with or without food and are available in 2 mg, 5 mg, 10 mg, 15 mg ...

June 20, 2007 — A large, international clinical trial in teens with schizophrenia demonstrated that the atypical antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical Co and Bristol-Myers Squibb) ...

Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Weight and ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

SAN DIEGO, May 23 -- Aripiprazole (Abilify) may be a useful adjunctive therapy in patients with major depressive disorders who have incomplete responses to antidepressants, researchers reported here.

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

The manufacturer presented direct clinical-effectiveness evidence from 2 randomised controlled trials comparing aripiprazole with placebo and performed a meta-analysis of these trials. The ...